Abstract
The aim of the present study was to test the efficacy of cis-coordinated complexes of platinum (II) with the polymer of benzene-poly-carboxylic acids derived from lignin (CDBPA) (laboratory code BP-C1), an innovative anticancer compound, on the growth of several solid human cancer cell lines: bladder cancer, chondrosarcoma, colonic cancer, head and neck cancer, hepatic cancer, ovary cancer, pancreatic cancer and prostatic cancer. Furthermore, the effect of CDBPA on non-Hodgkin lymphoma cell lines was also tested. The effect of CDBPA on cell viability was detected by XTT assay and toxicity was detected by measuring the leakage of Lactate dehydrogenase from the cells to the media. The present study has demonstrated that CDBPA is not toxic and able to reduce cell viability substantially and significantly in various human cancer cell lines. When comparison of viability in percentage of the controls at the maximum given dose of CDBPA for each type of cancer cell line, it was found that the largest impact on the viability was on sarcoma, and then decreases via breast, prostatic, head and neck-, pancreatic, colonic cancer and finally ovarian cancer. In addition, the effect of CDBPA on non-Hodgkin lymphoma cell lines was similar to that found in sarcoma cells. We conclude that the effect of CDBPA on cell viability is different and may be dependent on genotype of the cancer cell type. This may indicate different mechanisms of action in the different cancer types. The results obtained from the in vitro studies are important for designing future in vivo studies using animal models and to predict the clinical outcome in human cancer.
Highlights
The use of tissue culture methods in oncology has been performed for the last many decades, where Beebe and Ewing tried to grow lymphosarcoma in dogs [1]
We have used in vitro studies to determine the potential of the new innovative anti-cancer substance CDBPA (BP-C1) cis-coordinated complexes of platinum (II) with polymer of benzene poly-carboxylic acids derived from lignin, on the viability of human breast cancer cells
This study has demonstrated that the novel new anticancer product, CDBPA, is able to reduce cell viability substantially in various human cancer cell lines besides breast cancer cell lines as previously shown [2]
Summary
The use of tissue culture methods in oncology has been performed for the last many decades, where Beebe and Ewing tried to grow lymphosarcoma in dogs [1]. Improved cell culture techniques and application of molecular biology and genetic techniques will be more and more useful in the efficacy studies of anti-cancer drugs research as recommended by the European Community (Europe against cancer) [6]. We feel that in vitro testing can reduce the number of painful animal experiments to be reduced substantially This together with a methodology approach created to reduce the number of animals for research is an important issue [8]. We have used in vitro studies to determine the potential of the new innovative anti-cancer substance CDBPA (BP-C1) cis-coordinated complexes of platinum (II) with polymer of benzene poly-carboxylic acids derived from lignin, on the viability of human breast cancer cells. The efficacy of CDBPA was investigated in the two hematological cancer cell lines, non-Hodgkin lymphomas such as BL-2 and Ramos cell lines
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
